RT Journal Article
T1 A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.
A1 Berard, Emilie
A1 Röllig, Christoph
A1 Bertoli, Sarah
A1 Pigneux, Arnaud
A1 Tavitian, Suzanne
A1 Kramer, Michael
A1 Serve, Hubert
A1 Bornhäuser, Martin
A1 Platzbecker, Uwe
A1 Müller-Tidow, Carsten
A1 Baldus, Claudia D
A1 Martinez-Cuadron, David
A1 Serrano, Josefina
A1 Martinez-Sanchez, Pilar
A1 Arboli, Eduardo Rodriguez
A1 Gil, Cristina
A1 Bergua, Juan
A1 Bernal, Teresa
A1 de la Fuente Burguera, Adolfo
A1 Delabesse, Eric
A1 Bidet, Audrey
A1 Dumas, Pierre-Yves
A1 Montesinos, Pau
A1 Recher, Christian
K1 Leukemia, myeloid, acute
K1 Mutation
K1 Neoplasm recurrence, local
K1 Nuclear proteins
AB In a context of therapeutic revolution in older adults with AML, it is becoming increasingly important to select patients for the various treatment options by taking account of short-term efficacy and toxicity as well as long-term survival. Here, the data from three European registries for 1,199 AML patients aged 70 years or older treated with intensive chemotherapy were used to develop a prognostic scoring system. The median follow-up was 50.8 months. In the training set of 636 patients, age, performance status, secondary AML, leukocytosis, and cytogenetics, as well as NPM1 mutations (without FLT3-ITD), were all significantly associated with overall survival, albeit not to the same degree. These factors were used to develop a score that predicts long-term overall survival. Three risk-groups were identified: a lower, intermediate and higher-risk score with predicted 5-year overall survival (OS) probabilities of ≥12% (n = 283, 51%; median OS = 18 months), 3-12% (n = 226, 41%; median OS = 9 months) and <3% (n = 47, 8%; median OS = 3 months), respectively. This scoring system was also significantly associated with complete remission, early death and relapse-free survival; performed similarly in the external validation cohort (n = 563) and showed a lower false-positive rate than previously published scores. The European Scoring System ≥70, easy for routine calculation, predicts long-term survival in older AML patients considered for intensive chemotherapy.
PB Nature Publishing Group
YR 2022
FD 2022-06-22
LK http://hdl.handle.net/10668/19518
UL http://hdl.handle.net/10668/19518
LA en
NO Bérard E, Röllig C, Bertoli S, Pigneux A, Tavitian S, Kramer M, et al. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. Blood Cancer J. 2022 Jul 11;12(7):10
DS RISalud
RD Apr 11, 2025